Annexon, Inc.

NASDAQ:ANNX

Biotechnology

Healthcare
$3.52 -0.71%

-$0.04 today

Market cap
$576.73M
Beta
1.18
P/E (TTM)
-4.8
EPS (TTM)
-$1.01
52W Low $1.85High $7.18

Volume 2.98M

Average 2.56M

ANNX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Annexon, Inc.NASDAQ: ANNX

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 194.2M shares rose 31.1% year over year, ahead of the +14.3% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 25.2% from the prior quarter. Over 3 fiscal years it compounded at +41.6% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +31.1% holds above the trailing-twelve-month pace of +14.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
194.2M+25.2% QoQ
Last fiscal yearDec 2025
155.11M+12.9% YoY
LTMMar 2026
161.69M+14.3% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+31.1%——
1 year+12.9%——
3-year CAGR+41.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
155.11M USD
Year-over-year change
+12.9%
4-year CAGR
+41.8%

Weighted Avg Shares (Diluted) vs competitors

How ANNX compares with its peers on the latest reported figures

  • ANNX's LTM Mar 2026 weighted avg shares (diluted) of 161.69M shares is the 2nd highest of the 11 companies compared; the peer median is 72.23M shares.
  • Its year-over-year change of +14.3% is the 5th highest of 11, against a peer median of +7.9%.
  • Over three fiscal years its annual growth of +41.6% compares with a peer median of +14.5%.
ANNX Competitors Peer median
Weighted Avg Shares (Diluted) for ANNX and competitors
Company Period LTM YoY 3-year CAGR
IMVTImmunovant, Inc.LTM Sep 2026199.36M +24.0%+14.0%
ANNXAnnexon, Inc.LTM Mar 2026161.69M +14.3%+41.6%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026124.17M +37.8%+23.4%
ALMSAlumis Inc. Common StockLTM Jun 2026115.39M +93.6%+384.0%
ACIUAC Immune S.A.LTM Mar 202699.9M -0.5%+6.4%
XNCRXencor, Inc.LTM Jun 202674.94M +5.1%+7.6%
ABVXAbivax S.A.FY202569.53M +10.3%+53.9%
IFRXInflaRx N.V.LTM Mar 202668.86M +14.8%+15.0%
PRTAProthena Corporation plcLTM Mar 202653.9M -0.4%+4.4%
ANABAnaptysBio, Inc.LTM Mar 202629.47M +0.4%+3.6%
QTTBQ32 Bio Inc.LTM Mar 202612.78M +5.6%+56.9%
Peer median (excluding ANNX) 72.23M+7.9%+14.5%

Competitors are the stored peer set for ANNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0003.45M3.69M
Gross Profit000(3.45M)(3.69M)
Gross Margin—————
Research & Development100.07M112.5M113.76M119.45M184.7M
Selling, General & Admin30.65M30.95M28.02M34.63M31.71M
Operating Expenses130.71M145.6M143.72M150.62M212.72M
Depreciation & Amortization2.14M2.15M2.15M3.45M2.65M
EBITDA(128.18M)(139.8M)(132.09M)(134.75M)(204.04M)
EBITDA Margin—————
Operating Income(130.71M)(145.6M)(143.72M)(154.07M)(216.41M)
Operating Margin—————
Interest Income390K3.65M9.49M15.87M9.72M
Interest Expense00000
Other Income / Expenses390K3.65M9.49M15.87M9.72M
Income Before Tax(130.32M)(141.95M)(134.24M)(138.2M)(206.69M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(130.32M)(141.95M)(134.24M)(138.2M)(206.69M)
Net Margin—————
EPS (Basic)(3.34)(2.60)(1.77)(1.01)(1.34)
EPS (Diluted)(3.34)(2.60)(1.77)(1.01)(1.34)
Weighted Avg Shares38.32M54.67M75.67M137.4M155.11M
Weighted Avg Shares (Diluted)38.32M54.67M75.67M137.4M155.11M

Annexon, Inc.

NASDAQ:ANNX

Intrinsic Alpha fair value

Locked

Current Price

$3.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.